AFT Pharmaceuticals : FY 2021 AFT Financial PresentationOpens in a new Window

Working to improve your health

INVESTOR PRESENTATION MAY 2021

Investor presentation May 2021

Important Notice

This presentation has been prepared by AFT Pharmaceuticals Limited ("AFT"), to provide a general overview of the performance of AFT for the financial year ended 31 March 2021. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. This presentation should be read in conjunction with AFT's annual report, market releases and other periodic and continuous disclosure announcements, which are available at www.nzx.comand www.asx.com.au.

All amounts are disclosed in New Zealand dollars (NZ$) unless otherwise indicated. All references to FY20XX appearing in this presentation are to the financial year ending 31 March 20XX, unless otherwise indicated.

This presentation is not a recommendation, offer or invitation to acquire AFT's securities or other form of financial advice or disclosure document. While reasonable care has been taken in compiling this presentation, none of AFT nor its subsidiaries, directors, employees, agents or advisers (to the maximum extent permitted by law) gives any warranty or representation (express or implied) of the accuracy, completeness or reliability of the information contained in it nor takes any responsibility for it. The information in this presentation has not been and will not be independently verified or audited.

This presentation may contain certain forward-looking statements and comments about future events, including with respect to the financial condition, results, operations and business of AFT. These statements are based on management's current expectations, which may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct, and the actual events or results may differ materially and adversely from these statements.

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon (and is not) an indication of future performance.

2

Investor presentation May 2021

AFT financials at a glance

	120
																		113
( NZ$M)	100																106
				10 year operating CAGR of 13%
80														80	85
Revenue
60												64	69
											56
Operating
40										49
								40
						28	33	34
20					26
				23
				17
			12
	-	8
	'05	'06	'07	'08	'09	'10	'11	'12	'13	'14	'15	'16	'17	'18	'19	'20	'21

Financial year ended 31 March

		Operating profit¹						Profit after tax¹
15							10
10							5						7.7
5					11.4	10.7						2.8
			6.1	-
-									(2.4)
(9.0)						(5)	(13.2)		(12.6)
(5)		(10.1)
(14.8)				(10)	(18.4)
(10)
(15)							(15)
(20)	FY'16	FY'17	FY'18	FY'19	FY'20	FY'21	(20)	FY'16	FY'17	FY'18	FY'19	FY'20	FY'21

3	1 FY20 normalised to exclude $9.8m gain on de-recognition of equity accounted investment
	and recognition of net assets acquired at fair value in a step acquisition

Investor presentation May 2021

FY2021 financial highlights

54% Increase in number of countries Maxigesic sold in to	43

9% Increase in operating revenue from product sales to	$111.0m

6%	(+9% growth if adjusted for one off $1.7 million R&D credit in PY)	$10.7m
	Decline in normalised operating profit1 to

164% Increase in normalised profit after tax1 to	$7.8m

5% Improvement (decrease) in Net debt to	$35.2m

111% Increase in shareholders equity to

$36.5m

4

1 FY20 normalised to exclude $9.8m gain on de-recognition of equity accounted investment and recognition of net assets acquired at fair value in a step acquisition

Revenue Growth

		FY2020
	60.0	61.4
$ m	40.0
	20.0	30.1
	-	9.1	4.9

			FY2021		•	Continued growth in
	60.0	68.3
						established Australian
$ m	40.0						and New Zealand
						markets
	20.0		30.5
	-			9.9	4.4	•	Significant growth in
					product sales to Rest of
		11%	1%	8%	(10)%		the World

Investor presentation May 2021

4.7%8.6%

58.2%28.5%

47% product sales growth

3.9%

8.8%

27.0%

60.4%

• Significant margin improvement in Asia on lower revenue this year

5